Protocol for the Advancement of Histiocytic Diseases Biology
Understanding pathogenesis of histiocytic diseases is prerequisite to improving clinical and therapeutic strategies. Biological samples collected will be used to investigate genes and proteins that may better define the biology of histiocytic diseases. Additionally, biomarker discovery experiments may identify biomarkers that may be utilized as diagnostic or therapeutic targets in future protocols. Tissue will be collected, processed and stored with correlated clinical data to support specific aims as well as future research initiatives. This will be a companion biology study to NACHO clinical trials.
To determine the biological basis of histiocytic diseases and evaluate clinically relevant biomarkers.
Carl Allen, MD, PhD, Principal Investigator Texas Children’s Cancer Center/Baylor College of Medicine, Houston, TX USA
Michelle Hermiston, MD, PhD, Co-Investigator University of California San Francisco School of Medicine, San Francisco, CA USA
Michael Hogarty, MD, Co-Investigator The Children’s Hospital of Philadelphia/University of Pennsylvania, Philadelphia, PA USA
Michael B. Jordan, MD, Co-Investigator Cincinnati Children's Hospital Medical Center, Cincinnati, OH USA
Miriam Merad, MD, PhD, Co-Investigator Icahn School of Medicine at Mount Sinai, New York, NY USA
D. Williams Parsons, MD, PhD, Co-Investigator Baylor College of Medicine/Texas Children's Cancer Center, Houston, TX USA
Carlos Rodriguez-Galindo, MD, Co-Principal Investigator St. Jude Children's Research Hospital, Memphis, TN USA
Barrett Rollins, MD, PhD, Co-Investigator Harvard Medical School/Dana-Farber Cancer Institute, Boston, MA USA